This 2022 study gave 5-Loxin, a standardised Boswellia serrata extract, by mouth to rats with chemically induced joint damage. Treated rats had less joint pain, lower COX-2, 5-LOX, prostaglandin E2 and leukotriene B4, and better preserved glycosaminoglycans and aggrecan, which the authors tied to lower matrix metalloproteinases.
Researchers injected monosodium iodoacetate (MIA, 50 µL at 60 mg/mL) into rats' knee joints to damage the cartilage, a standard model. They gave the extract by mouth and assessed the rats with blood tests, real-time PCR for gene activity, tissue staining and micro-CT scans of the joint.
The extract relieved joint pain in the rats and held back cartilage degeneration. It suppressed the inflammatory enzymes COX-2 and 5-lipoxygenase, with significant falls in prostaglandin E2 and leukotriene B4. It reduced damage to glycosaminoglycans and aggrecan, the main components of the cartilage matrix, and the authors attribute this to lower matrix metalloproteinases.
The abstract does not give the dose, the number of rats or the length of treatment. It reports matrix metalloproteinases as a group and does not name MMP13. The MIA model damages cartilage with a chemical, which is not how cartilage loss usually happens in people, and rat doses do not translate directly to human ones.
It shows a Boswellia serrata extract acting on the matrix-cutting enzymes in a living animal after being swallowed, rather than added to cells. That bridges the lab work and the human trials, though the abstract stops short of naming MMP13, so it shows the enzyme family responding rather than MMP13 itself.
In animal and lab studies, yes. AKBA, the lead boswellic acid, suppressed MMP13 in rats with chemically induced knee damage, and a frankincense extract lowered MMP13...
Yes, in lab studies. The inflammatory messenger IL-1 raised MMP13 in human cartilage and cartilage cells in several studies, and TNF-alpha did too. To switch the MMP13...